These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15327020)

  • 41. CSF substance P somatostatin and monoaminergic transmitter metabolites in patients with narcolepsy.
    Strittmatter M; Isenberg E; Grauer MT; Hamann G; Schimrigk K
    Neurosci Lett; 1996 Nov; 218(2):99-102. PubMed ID: 8945737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evidence for heritability of biogenic amine levels in the cerebrospinal fluid of rhesus monkeys.
    Clarke AS; Kammerer CM; George KP; Kupfer DJ; McKinney WT; Spence MA; Kraemer GW
    Biol Psychiatry; 1995 Nov; 38(9):572-7. PubMed ID: 8573659
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Somatostatin, its molecular forms and monoaminergic transmitter metabolites in Binswanger's disease. Neurochemical-neuropathological considerations.
    Strittmatter M; Grauer MT; Hamann GF; Cramer H; Schimrigk K
    Neurodegeneration; 1996 Dec; 5(4):359-66. PubMed ID: 9117548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Folate deficiency, biopterin and monoamine metabolism in depression.
    Bottiglieri T; Hyland K; Laundy M; Godfrey P; Carney MW; Toone BK; Reynolds EH
    Psychol Med; 1992 Nov; 22(4):871-6. PubMed ID: 1283223
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.
    Strittmatter M; Hamann GF; Strubel D; Cramer H; Schimrigk K
    J Neural Transm (Vienna); 1996; 103(5):591-602. PubMed ID: 8811504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Milacemide effects on the temporal inter-relationship of amino acids and monoamine metabolites in rat cerebrospinal fluid.
    Semba J; Patsalos PN
    Eur J Pharmacol; 1993 Jan; 230(3):321-6. PubMed ID: 8440309
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Variations of homovanillic acid levels in ventricular cerebrospinal fluid.
    Hildebrand J; Moussa Z; Raftopoulos C; Vanhouche J; Laute MA; Przedborski S
    Acta Neurol Scand; 1992 May; 85(5):340-2. PubMed ID: 1621497
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cerebrospinal fluid levels of monoamines in patients with Japanese encephalitis.
    Kusuhara T; Ayabe M; Hino H; Shoji H; Yamada S
    Eur Neurol; 1996; 36(4):236-7. PubMed ID: 8814430
    [No Abstract]   [Full Text] [Related]  

  • 49. Cinnarizine-induced parkinsonism in primates.
    García Ruiz PJ; Mena MA; Peñafiel N; De Yébenes JG
    Clin Neuropharmacol; 1992 Apr; 15(2):152-4. PubMed ID: 1375537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A 2-year prospective follow-up study of children and adolescents with disruptive behavior disorders. Prediction by cerebrospinal fluid 5-hydroxyindoleacetic acid, homovanillic acid, and autonomic measures?
    Kruesi MJ; Hibbs ED; Zahn TP; Keysor CS; Hamburger SD; Bartko JJ; Rapoport JL
    Arch Gen Psychiatry; 1992 Jun; 49(6):429-35. PubMed ID: 1376104
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monoamines and their metabolites in cerebrospinal fluid and temporal cortex of epileptic patients.
    Naffah-Mazzacoratti MG; Amado D; Cukiert A; Gronich G; Marino R; Calderazzo L; Cavalheiro EA
    Epilepsy Res; 1996 Oct; 25(2):133-7. PubMed ID: 8884171
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Infantile-onset paroxysmal dystonia: a diagnostic dilemma.
    Wilmshurst JM; Howman-Giles R; Antony J
    J Child Neurol; 2001 Mar; 16(3):222-5. PubMed ID: 11305692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+.
    Espino A; Ambrosio S; Bartrons R; Bendahan G; Calopa M
    J Neural Transm Park Dis Dement Sect; 1994; 7(3):167-76. PubMed ID: 7710669
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Factors governing the composition of the cerebrospinal fluid.
    Lorenzo AV
    Exp Eye Res; 1977; 25 Suppl():205-28. PubMed ID: 338318
    [No Abstract]   [Full Text] [Related]  

  • 55. Evidence for reduced homovanillic acid (HVA) in the cerebrospinal fluid of patients with depression.
    Ogawa S; Kunugi H
    J Affect Disord; 2019 Aug; 255():. PubMed ID: 31006502
    [No Abstract]   [Full Text] [Related]  

  • 56. Low level of evidence for reduced homovanillic acid (HVA) in the cerebrospinal fluid of patients with depression compared to healthy non-psychiatric control individuals.
    Knorr U; Forman J; Pech J; Kessing LV
    J Affect Disord; 2019 Oct; 257():585-588. PubMed ID: 31326691
    [No Abstract]   [Full Text] [Related]  

  • 57. Monoamine metabolites in the cerebrospinal fluid in infantile spinal muscular atrophy.
    Takeuchi Y; Komatsu H; Matsuo S; Hirai K; Kawase S; Nishimura A; Sawada T
    Neuroreport; 1994 Apr; 5(8):898-900. PubMed ID: 8061291
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analytical Method Validation for Estimation of Neurotransmitters (Biogenic Monoamines) from Cerebrospinal Fluid Using High Performance Liquid Chromatography.
    Lokhande RV; Bhagure GR; Dherai AJ; Naik PR; Udani VP; Desai NA; Ashavaid TF
    Indian J Clin Biochem; 2022 Jan; 37(1):85-92. PubMed ID: 35125697
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Developmental changes in cerebrospinal fluid concentrations of monoamine-related substances revealed with a Coulochem electrode array system.
    Takeuchi Y; Matsushita H; Sakai H; Kawano H; Yoshimoto K; Sawada T
    J Child Neurol; 2000 Apr; 15(4):267-70. PubMed ID: 10805197
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 5-Hydroxyindoleacetic acid in cerebrospinal fluid--methodological and clinical aspects.
    Bertilsson L
    Life Sci; 1987 Aug; 41(7):821-4. PubMed ID: 2441222
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.